Acyl Ghrelin Improves Synapse Recovery in an In Vitro Model of Postanoxic Encephalopathy

Irina I. Stoyanova1 · Jeannette Hofmeijer1,3 · Michel J. A. M. van Putten1,4 · Joost le Feber1,2

Received: 8 August 2015 / Accepted: 19 October 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Comatose patients after cardiac arrest have a poor prognosis. Approximately half never awakes as a result of severe diffuse postanoxic encephalopathy. Several neuroprotective agents have been tested, however without significant effect. In the present study, we used cultured neuronal networks as a model system to study the general synaptic damage caused by temporary severe hypoxia and the possibility to restrict it by ghrelin treatment. Briefly, we applied hypoxia (pO2 lowered from 150 to 20 mmHg) during 6 h in 55 cultures. Three hours after restoration of normoxia, half of the cultures were treated with ghrelin for 24 h, while the other, non-supplemented, were used as a control. All cultures were processed immunocytochemically for detection of the synaptic marker synaptophysin. We observed that hypoxia led to drastic decline of the number of synapses, followed by some recovery after return to normoxia, but still below the prehypoxic level. Additionally, synaptic vulnerability was selective: large- and small-sized neurons were more susceptible to synaptic damage than the medium-sized ones. Ghrelin treatment significantly increased the synapse density, as compared with the non-treated controls or with the prehypoxic period.

The effect was detected in all neuronal subtypes. In conclusion, exogenous ghrelin has a robust impact on the recovery of cortical synapses after hypoxia. It raises the possibility that ghrelin or its analogs may have a therapeutic potential for treatment of postanoxic encephalopathy.

Keywords Brain hypoxia · Postanoxic encephalopathy · Synapse density · Ghrelin

Introduction

Comatose patients after cardiac arrest have a poor prognosis. Approximately half never awakes as a result of severe diffuse postanoxic encephalopathy [1]. Several neuroprotective agents such as barbiturates [2], calcium channel blockers [3, 4], magnesium [5], and diazepam [6] have been tested, however without significant effect. The only treatment of proven benefit is mild therapeutic hypothermia [7, 8], although the gain of this treatment has become uncertain since the recent Targeted Temperature Management (TTM) trial [9]. An important rationale behind all neuroprotective strategies, including hypothermia, has been prevention of secondary damage by inhibition of activation. This should preserve remaining energy levels in order to maintain membrane voltage and basic cellular processes and prevent excitotoxicity [10]. In acute ischemic stroke, where part of the same mechanisms play a role, many modalities have been tested based on the same argumentation [11]. Neither in postanoxic coma nor in ischemic stroke were any of these beneficial in clinical trials.

The initial encephalopathy after cardiac arrest results from a global decrease of cerebral perfusion to a level that is insufficient to meet the brain’s high metabolic demands [12]. Classically, the resulting ATP depletion is associated with failure of transmembrane ion pumps, depolarization, cell swelling,
and cell death [13]. However, in imaging studies, sings of cell swelling and necrosis were only moderately associated with severity of encephalopathy and even absent in almost half of patients, despite lasting severe encephalopathy and a poor outcome [14]. Other pathophysiological mechanisms leading to brain malfunctioning include local acidosis, free radical formation, and nitric oxide production. Functional changes are caused by damage to mitochondria, cytoskeleton, and glutamate receptors [15, 16].

In animal models of acute ischemic stroke, synaptic failure through impaired transmitter release was an early consequence of ischemia and led to irreversible cerebral network damage in the absence of cell swelling or necrosis [17]. Synaptic transmission disturbances cause a lack of postsynaptic activation and consequently decreased network activity [18]. Since long-term suppression of activity leads to permanent damage [19, 20] and lack of brain activity during more than 24 h is strongly associated with absence of recovery from postanoxic coma [21, 22], it is argued that mild excitation such as caused by ghrelin, instead of inhibition, may be of benefit.

Previously, we have shown improvements of network connectivity along with an increased number of synapses, resulting from chronic stimulation of dissociated cortical neurons with ghrelin [23, 24]. Ghrelin is multifunctional 28-aminoacid hormone and a neuropeptide originally not only found in the rat stomach [25], but also identified in the hypothalamus, to a lesser extent in the hippocampus and brain cortex [26–28], as well as in the adipose tissue [29]. Ghrelin gene encodes a precursor which is cleaved to produce first unacylated ghrelin (des-acyl ghrelin (DAG)) further transformed into acyl ghrelin (AG, also referred to as ghrelin) by esterification of the serine-3 residue with n-octanoic acid [30]. AG binds to the growth hormone secretagogue receptor 1a isoform (GHSR1) [25], which is expressed in the cerebral cortex in vivo [27], as well as in dissociated cortical neurons [23], and is responsible for some of the central and peripheral effects of ghrelin [31]. As recently reported, ghrelin enhances synaptic plasticity [26], memory consolidation [32], and adult neurogenesis [33, 34]. Here, we show that ghrelin improves synaptic recovery in an in vitro model of postanoxic encephalopathy consisting of cultured neuronal networks exposed to severe hypoxia.

**Material and Methods**

We used an in vitro model of postanoxic encephalopathy consisting of cultured neuronal networks exposed to severe hypoxia for 6 h, followed by a recovery period with normoxia during 3 h. Thereafter, half of the cultures were supplemented with ghrelin for 24 h, while the other half were not manipulated pharmacologically and used as a control. Before induction of hypoxia and after each experimental phase, part of the neuronal cultures were fixed and processed for detection and quantitative evaluation of the synaptic marker synaptophysin (SPh). The study design is illustrated in Fig. 1.

**Dissociated Cell Cultures**

Cell cultures were obtained from Wistar rat pups, from eight plating procedures, five pups (from the same mother) per plating. The animals were anesthetized with isoflurane and decapitated. The brains were removed and placed in RPMI medium (developed at Roswell Park Memorial Institute, hence the
acronym RPMI). After removal of the meninges, cortical cells were dissociated and collected in chemically defined R12 culture medium [35] with trypsin for chemical dissociation. Thereafter, 150 μl of soybean trypsin inhibitor and 125 μl of DNase I (20,000 units, Life Technology) were added, followed by titration for mechanical dissociation of the neurons. The suspension was centrifuged at 1200 rpm for 5 min. Cells were plated on glass coverslips at a density of approximately 3000 cells/mm². The glass coverslips were precoated with 20 mg/ml polyethyleneimine (Fluka, Buchs, Switzerland) to enhance cell adhesion. Cells were allowed to attach for 2 h at 37 °C and 5 % CO₂ in air and thereafter kept in R12 medium, optimized with 50 ng/ml nerve growth factor (Invitrogen, Carlsbad, CA). The medium was serum-free to suppress glial cell proliferation, keeping their concentration lower than 5 % [35]. The medium was renewed every 2–3 days. Cultures were stored in an incubator under standard conditions of 36 °C, 100 % humidity, and 5 % CO₂ for a period of 3–4 weeks, till the neurons established mature synaptic contacts. All animal experiments were conducted according to Dutch law (as stated in the “Wet op de dierproeven”) and approved by the Utrecht Animal Use Committee (DEC).

**Induction of Hypoxia and Pharmacological Manipulation**

For induction of hypoxia, the well plates with neuronal cultures were placed under a Plexiglass hood (volume ~5 L). Temperature, humidity, and CO₂ level of the environment were maintained as in the incubator. Two mass flow controllers were used to mix air and N₂ and to produce a total flow of 4.7 L/min under the hood. Under physiological conditions, the gas mixture consisted of ambient air with 5 % CO₂. For induction of hypoxia, 90 % of the air was replaced by N₂ during 6 h, lowering the partial oxygen pressure (pO₂) in the bath from ~150 to ~20 mm Hg. Restoration of normoxia followed thereafter. To obtain an estimate of the course of the oxygen concentration in the culture medium, pO₂ was measured using an optical oxygen sensor (PHOSPOR, Ocean Optics), which was inserted into the wells, near the neurons.

Three hours after restoration of normoxia, half of the remaining cultures were supplemented with ghrelin (Abcam, Cambridge, UK) for 24 h, at a final concentration of 1 μM, as described elsewhere [24, 26, 27, 36, 37]. The other half of the cultures were kept in a plain medium, also for 24 h, and used as control.

**Immunohistochemistry**

SPh staining was done on 55 cultures, equally distributed over the experimental phases (baseline, 6-h hypoxia, 3-h normoxia, 24 h Ghr, or 24 h Ctrl). Cultures were fixed in 4 % paraformaldehyde in 0.1 M PBS, pH 7.4, and processed immunocytochemically with the avidin-biotin-horseradish peroxidase (ABC) method [38] to detect the synaptic marker. Briefly, hydrogen peroxide (0.3 % in absolute methanol for 30 min) was used to inactivate endogenous peroxidase. Appropriate washes in PBS followed this and subsequent treatments. Incubation in primary antibody mouse anti-SPh IgG (Abcam, Cambridge, UK, dilution 1:1000) lasted for 20 h at room temperature, followed by 2 h in biotinilated donkey anti-mouse IgG (1:500; Jackson ImmunoResearch, West) and 1 h in ABC (1:500; Vector Labs, Burlingame, CA, USA). Following rinsing, peroxidase activity was visualized with 2.4 % SG substrate kit for peroxidase (Vector) in PBS for 5 min, at room temperature. Finally, the cultures were dehydrated in a graded series of alcohols, cleared in xylene, and coverslipped with Entellan (Merck, Darmstadt, Germany).

The immunoreactivity was readily discernible at the light microscopic level by the presence of dark-gray granules of immunoreactive (IR) product. Neuronal structures were considered to be immunopositive when their staining was clearly stronger than that in the background. Negative controls included incubation after antigen-antibody preabsorption with the native antigen, at 4 °C for 24 h, or replacement of the primary antibody with non-immune serum at the same concentration.

**Photomicrograph Production and Data Analysis**

After staining, micrographs were generated at ×60 using a Nikon DS-Fi1 digital camera linked to a Nikon Eclipse 50i microscope. All digital images were matched for brightness in Adobe Photoshop 7.0. For quantification of the synaptic marker expression, we counted the number of granules of reaction product after SPh staining. Counting was done blinded to treatment allocation. We obtained estimates of the neuronal size, the number of SPh-IR granules, and the size of the area in which they were counted by means of Nikon NIS-Elements software. To avoid bias due to the small diameter of the neurites and differences in the cell density across the cultures, we restricted this analysis to the area of the perikarya and the initial part of the arborizations.

To guarantee inclusion of neurons of various sizes in our analysis, we defined small-sized (surface of the perikaryon <100 μm²), medium-sized (cell 100–200 μm²), and large-sized neurons (cells >200 μm²) [39–41]. Additionally, we qualitatively graded the overall density of immunostaining of neurons into two categories, high and low, following the procedure described by Ljungdahl et al. [42]. Ten neurons from each category (low and high IR) were examined in each neuronal group (large, medium, or small sized) under each condition (baseline, 6-h hypoxia, 3-h normoxia, 24 h Ghr, or 24 h Ctrl). Thus, 60 neurons per condition were evaluated, obtained from 9 to 12 cultures per condition. SPh-IR granule density was calculated and presented as mean±standard deviation (SD). Student’s t tests and a non-parametric Kruskal-Wallis test with post hoc Tukey HSD were applied to assess
statistical significance of differences in SPh expression between the various groups of neurons and conditions. \( P \) values <0.05 were considered statistically significant.

**Results**

Granules of SPh-IR product were localized on the neuronal somata and along the neurites. Their density varied according to experimental condition and according to neuronal size. Typical examples of SPh-IR neurons from each condition group are shown in Fig. 2.

**SPh Density According to Experimental Condition**

Hypoxia significantly reduced SPh density (0.28±0.06 granules/μm²) compared with baseline (0.34±0.1 granules/μm², \( p=0.0002 \)). The posthypoxic values did not return to the baseline levels, neither 3 h after restoration of normoxia (0.27±0.07 granules/μm²) nor 24 h later (0.28±0.15 granules/μm²). However, after ghrelin treatment at 3 h, SPh density at 24 h (0.48±0.1 granules/μm²) was statistically significant higher than in the control group (0.28±0.15 granules/μm², \( p<0.001 \)) and at baseline (0.34±0.1 granules/μm², \( p=0.001 \)). The quantitative data are presented in Table 1.

**SPh Density According to Neuronal Size**

Synapse density varied according to neuronal size. At baseline, densities were 0.38±0.08, 0.30±0.06, and 0.40±0.12 granules/μm² for large-, medium-, and small-sized neurons. Hypoxia significantly downregulated the number of synaptic contacts of the large neurons (0.29±0.07 granules/μm², \( p=0.0004 \)). This was irreversible: the density continued to decrease after restoration of normoxia (0.24±0.07 granules/μm² after 3 h and 0.23±0.14 granules/μm² 24 h later). Unlike in the large neurons, once reduced by hypoxia, SPh density of small neurons (0.28±0.06 granule/μm²) remained unchanged during the posthypoxic periods (0.27±0.05 granules/μm² (3-h restoration) and 24 h later (0.31±0.16 granules/μm² in 24 h Ctrl). Synapse density of medium-sized neurons did not show sensitivity to hypoxia. It did not change by exposure to hypoxia (0.27±0.06 granules/μm²) and remained unchanged after normoxia restoration (0.31±0.05 granules/μm² at 3 h and 0.28±0.09 granules/μm² 24 h later). Ghrelin significantly increased SPh density in the three neuronal subtypes. Treatment effect was largest in the small-sized neurons (Table 2).

**Discussion**

In an in vitro model of postanoxic encephalopathy consisting of cultured neurons exposed to temporary severe hypoxia, we
show a significant reduction of synaptic density (from 0.34 to 0.28 granules/μm², \(p=0.0002\)). Additionally, we demonstrate that treatment with ghrelin initiates recovery (from 0.28 to 0.48 granules/μm², \(p<0.001\)) and leads to complete restoration of the synaptic density in all subtypes of neurons according to their size, with most prominent effect on the medium-sized ones (from 0.28 to 0.48 granules/μm², \(p<0.001\)).

Our results are in line with previous in vitro and in vivo studies, showing that hypoxia or ischemia affects synaptic transmission before disruption of ion gradients across the plasma membrane [43–46]. Several causes for presynaptic and postsynaptic ischemic failure have been proposed [17]. The initial disturbances are probably located presynaptically rather than postsynaptically, with impaired transmitter release [17], decreased presynaptic dense projections [47], and isolated loss of presynaptic buttons [48]. Failure of synaptic transmission has been proposed to account for electric silence in the penumbra of a brain infarct [49] and has been associated with lasting network damage in the absence of depolarization in a rat model of cerebral infarction [45]. In addition, perinatal exposure to hypoxia caused early degenerative processes in existing synapses, decline in synaptogenesis, and a more than twofold reduction of synaptic density in all cortical layers of the rat, as shown by SPh immunodetection [50]. Cerebral ischemia induces interaction of the postsynaptic density (PSD-95) with neuronal nitric oxide synthase (nNOS), thereby leading to nitric oxide (NO) overproduction and neuronal injury [51]. Disruption of this coupling enhances neurite growth and dendritic spine formation and thus improves stroke outcome by promoting regenerative processes [52].

Further research on the effect of hypoxia on postsynaptic density and dendritic spine distribution would be clinically relevant.

Previously demonstrated selective ischemic damage affected striatum, hippocampal pyramidal neurons, cerebellar Purkinje cells, and the neocortical pyramidal cells [53–55] with relatively strong downregulation of synapse density [48]. In the cortex, we also observed selective vulnerability: large- and small-sized neurons were more susceptible to synaptic damage than medium-sized neurons. In general, neuronal morphology correlates with certain neuronal functions, and as the fundamental work of McConnell indicated, the large-sized neurons convey afferent sensory signals from subcortical regions and efferent signaling to subcortical areas, while the small-sized neurons are involved in efferent intracortical transmission [56]. Therefore, we could speculate that the primary sensory and motor systems are more vulnerable to ischemic damage. Such morphological evidence for selective vulnerability of the primary sensory and motor system was demonstrated in a model of asphyxic cardiac arrest in newborn piglets [57] and confirmed electrophysiologically in rodents [58]. Causes of selective vulnerability are still unclear; however, it is possible to be related to specific oxidative metabolism [57].

Previously, we reported that AG accelerates synaptogenesis and synaptic activity under healthy conditions [23, 24]. Supposed working mechanisms for stimulating synapse growth or recovery include activation of several signaling pathways. By activating GHSR1, ghrelin increases Ca²⁺ influx [59, 60] and intracellular Ca²⁺ mobilization [61] which

### Table 1 Density of SPh granules under different experimental conditions

| Condition     | Number of cultures evaluated | Number of neurons evaluated | SPh density (granules/μm²) | SD    |
|---------------|------------------------------|----------------------------|---------------------------|-------|
| Baseline      | 11                           | 60                         | 0.34                      | ±0.10 |
| 6-h hypoxia   | 9                            | 60                         | 0.28 (**\(p=0.0002\))     | ±0.06 |
| 3-h Normoxia  | 12                           | 60                         | 0.27 (**\(p=6.5.10^{-5}\)) | ±0.07 |
| 24 h Control  | 11                           | 60                         | 0.28 (*\(p=0.0134\))      | ±0.15 |
| 24 h Ghr      | 12                           | 60                         | 0.48 (**\(p=2.10^{-13}\)) | ±0.10 |

*Asterisks indicate significant change from baseline: *\(p<0.05\); **\(p<0.001\)

### Table 2 SPh density in different neuronal types under all experimental conditions

| Neuronal subtype | Mean SPh density (granules/μm²)±SD |
|------------------|------------------------------------|
|                  | Baseline 6-h hypoxia 3-h normoxia 24 h Ctrl 24 h Ghr |
| Large            | 0.38±0.08 0.29±0.07 (**\(p=4.10^{-4}\)) 0.24±0.07 (**\(p=1.3.10^{-6}\)) 0.23±0.14 (**\(p=2.8.10^{-5}\)) 0.45±0.08 (*\(p=0.01\)) |
| Medium           | 0.30±0.06 0.27±0.06 0.31±0.05 0.28±0.09 0.48±0.09 (**\(p=1.1.10^{-5}\)) |
| Small            | 0.40±0.12 0.28±0.06 (**\(p=3.8.10^{-4}\)) 0.27±0.05 (**\(p=1.4.10^{-4}\)) 0.31±0.16 (*\(p=0.04\)) 0.52±0.12 (*\(p=0.003\)) |

*Asterisks indicate significant change from baseline: *\(p<0.05\); **\(p<0.001\)
results in synaptic gene nuclear factor expression [62]. Furthermore, as an excitatory neurotransmitter, ghrelin stimulates synaptic activity, which triggers additional synthesis and aggregation of neurotransmitter receptors [63] and other types of synaptic signaling molecules like agrin [64]. In the cerebral cortex, agrin is associated with excitatory but not inhibitory synapses [65]. It stimulates formation and stabilization of dendritic filopodia and consequently promotes synaptogenesis [66]. Additionally, agrin induces a switch from gap junction-mediated communication to synaptic transmission [67]. Considering that gap junctions respond to hypoxia-ischemia by excessive channel opening which spreads the injury [68, 69], it is reasonable to hypothesize a role for ghrelin in the restriction of ischemic injury and upregulation of the synaptic assembly via agrin-mediated mechanism.

Beneficial effects of ghrelin have been observed in animal models of acute ischemic stroke. In a rat model, administration of ghrelin reduces infarct volume and cell death [70] by preventing apoptosis and improving mitochondrial function [71]. Thus, in addition to the stimulating effect on the synaptic survival, ghrelin further ameliorates cellular respiration and network recovery from severe hypoxia.

We used cultured neuronal networks as a model system to study the effects of temporary severe hypoxia. An important advantage of this model system is that, unlike acute brain slices, cultures can stay alive for several days up to months. In addition, many neurons and synapses in a network can be studied simultaneously. A possible limitation is the lack of normal brain architecture, as present in acute brain slices. However, the focus of this study was on general synaptic damage and recovery, which does not require a specific brain structure. The system has been used before, but with a focus on anoxia-induced neuronal death instead of synaptic function [72].

In conclusion, the present observations support the hypothesis that exogenous ghrelin has a robust impact on the recovery of cortical synapses after hypoxia. It raises the possibility that ghrelin or its analogs may have a therapeutic potential for treatment of postanoxic encephalopathy.

**References**

1. Zandbergen EG et al (1998) Systematic review of early prediction of poor outcome in anoxic-ischaemic coma. Lancet 352(9143):1808–1812
2. (1986) Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. N Engl J Med 314(7):397–403
3. Group, B.R.C.T.I.S. (1991) A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group. N Engl J Med 324(18):1225–1231
4. Roine RO et al (1990) Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. JAMA 264(24):3171–3177
5. Thel MC et al (1997) Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet 350(9087):1272–1276
6. Longstreth WT Jr et al (2002) Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. Neurology 59(4):506–514
7. Group, H.A.C.A.S (2002) Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 346(8):549–556
8. Bernard SA et al (2002) Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 346(8):557–563
9. Nielsen N et al (2013) Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med 369(23):2197–2206
10. Andresen M et al (2015) Therapeutic hypothermia for acute brain injuries. Scand J Trauma Resusc Emerg Med 23:42
11. Ginsberg MD (2008) Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55(3):363–389
12. Symon L et al (1977) The concepts of thresholds of ischaemia in relation to brain structure and function. J Clin Pathol Suppl (R Coll Pathol) 11:149–154
13. Gutierrez LG et al (2010) CT and MR in non-neonatal hypoxic-ischemic encephalopathy: radiological findings with pathophysiological correlations. Neuroradiology 52(11):949–976
14. Mlynash M et al (2010) Temporal and spatial profile of brain diffusion-weighted MRI after cardiac arrest. Stroke 41(8):1665–1672
15. Tsai YW et al (2013) Post ischemia intermittent hypoxia induces hippocampal neurogenesis and synaptic alterations and alleviates long-term memory impairment. J Cereb Blood Flow Metab 33(5):764–773
16. Sun MK et al (2008) Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Natl Acad Sci U S A 105(36):13620–13625
17. Hofmeijer J, van Putten MJ (2012) Ischemic cerebral damage: an appraisal of synaptic failure. Stroke 43(2):607–615
18. Hofmeijer J et al (2014) Mild hypoxia affects synaptic connectivity in cultured neuronal networks. Brain Res 1557:180–189
19. Ghosh A, Carnahan J, Greenberg ME (1994) Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263(5153):1618–1623
20. Butz M, Worgetter F, van Ooyen A (2009) Activity-dependent structural plasticity. Brain Res Rev 60(2):287–305
21. Tjepkema-Cloostermans MC et al (2015) Electroencephalogram predicts outcome in patients with postanoxic coma during mild therapeutic hypothermia. Crit Care Med 43(1):159–167
22. Hofmeijer J et al. (2015) Early EEG contributes to multimodal outcome prediction of postanoxic coma. Neurology
23. Stoyanova II, le Feber J, Rutten WL (2014) Ghrelin accelerates synaptic formation and activity development in cultured cortical networks. BMC Neurosci 15:49
24. Stoyanova II, le Feber J (2014) Ghrelin stimulates synaptic formation in cultured cortical networks. Regul Pept 186:43–48
25. Kojima M et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762):656–660
26. Diano S et al (2006) Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 9(3):381–388
27. Cowley MA et al (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37(4):649–661
28. Stoyanova II, Wiertz RW, Rutten WL (2009) Time-dependent changes in ghrelin-immunoreactivity in dissociated neuronal cultures of the newborn rat neocortex. Regul Pept 158(1–3):86–90
29. Serbedzija G et al (2015) Roles of leptin and ghrelin in adipogenesis and lipid metabolism of rainbow trout adipocytes in vitro. Comp Biochem Physiol A Mol Integr Physiol 188:40–48
30. Hosoda H et al (2000) Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279(3):909–913
31. van der Lely AJ (2009) Ghrelin and new metabolic frontiers. Horm Res 71(Suppl 1):129–133
32. Kang S et al (2015) Central acylated ghrelin improves memory function and hippocampal AMPK activation and partly reverses the impairment of energy and glucose metabolism in rats infused with beta-amyloid. Peptides 71:84–93
33. Li E et al (2013) Ghrelin directly stimulates adult hippocampal neurogenesis: implications for learning and memory. Endocr J 60(6):781–789
34. Kent BA et al (2015) The orexigenic hormone acyl-ghrelin increases adult hippocampal neurogenesis and enhances pattern separation. Psychoneuroendocrinology 51:431–439
35. Romijn HJ, van Huizen F, Wolters PS (1984) Towards an improved cerebral cortex tissue. Neurosci Biobehav Rev 8(3):301–334
36. Johansson I et al (2008) Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. Endocrinology 149(5):2191–2199
37. Cecarini V et al. (2015) Effects of ghrelin on the proteolytic pathways of Alzheimer’s disease neuronal cells. Mol Neurobiol
38. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29(4):577–580
39. Gittins R, Harrison PJ (2004) Neuronal density, size and shape in the human anterior cingulate cortex: a comparison of Nissl and NeuN staining. Brain Res Bull 63(2):155–160
40. Gittins R, Harrison PJ (2004) A quantitative morphometric study of the human anterior cingulate cortex. Brain Res 1013(2):212–222
41. Unger JW, Lange W (1992) NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuromatopy, peptidergic characteristics and aspects of aging and Alzheimer’s disease. Acta Neuropathol 83(6):636–646
42. Ljungdahl A, Hokfelt T, Nilsson G (1978) Distribution of substance P-like immunoreactivity in the central nervous system of the rat—I. Cell bodies and nerve terminals. Neuroscience 3(10):861–943
43. Leblond J, Krnjevic K (1989) Hypoxic changes in hippocampal neurons. J Neurophysiol 62(1):1–14
44. Fujiwara N et al (1987) Effects of hypoxia on rat hippocampal neurons in vitro. J Physiol 384:131–151
45. Bolay H et al (2002) Persistent defect in transmitter release and synapsin phosphorylation in cerebral cortex after transient moderate ischemic injury. Stroke 33(5):1369–1375
46. Sun MK, Xu H, Alkon DL (2002) Pharmacological protection of synaptic function, spatial learning, and memory from transient hypoxia in rats. J Pharmacol Exp Ther 300(2):408–416
47. Stepanov SS et al (1998) An ultrastructural study into the effect of global transient cerebral ischaemia on the synaptic population of the cerebellar cortex in rats. Resuscitation 39(1–2):99–106
48. Horner CH, Davies HA, Stewart MG (1998) Hippocampal synaptic density and glutamate immunoreactivity following transient cerebral ischaemia in the chick. Eur J Neurosci 10(12):3913–3917
49. Astrup J, Siesjo BK, Symon L (1981) Thresholds in cerebral ischaemia—the ischemic penumbra. Stroke 12(6):723–725
50. Otelin VA, Khozhati LJ, Shishko TT (2014) Reactions of the interneuronal synapses of rat brain to hypoxia during the early postnatal period. Morphologia 145(1):7–12
51. Zhou L et al (2010) Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med 16(12):1439–1443
52. Luo CX et al (2014) Interaction of nNOS with PSD-95 negatively controls regenerative repair after stroke. J Neurosci 34(40):13535–13548
53. Cervos-Navarro J, Diemer NH (1991) Selective vulnerability in brain hypoxia. Crit Rev Neurobiol 6(3):149–182
54. Bendel O et al (2005) Reappearance of hippocampal CA1 neurons after ischaemia is associated with recovery of learning and memory. J Cereb Blood Flow Metab 25(12):1586–1595
55. Schwartz PH et al (1992) A rat model of severe neonatal hypoxic-ischemic brain injury. Stroke 23(4):539–546
56. McConnell SK (1991) The generation of neuronal diversity in the central nervous system. Annu Rev Neurosci 14:269–300
57. Martin LJ et al (1997) Primary sensory and forebrain motor systems in the newborn brain are preferentially damaged by hypoxia-ischemia. J Comp Neurol 377(2):262–285
58. Wu D et al (2012) Short- and long-latency somatosensory neuronal responses reveal selective brain injury and effect of hypothermia in global hypoxic ischemia. J Neurophysiol 107(4):1164–1171
59. Hosoda H, Kojima M, Kangawa K (2006) Biological, physiological, and pharmacological aspects of ghrelin. J Pharmacol Sci 100(5):398–410
68. Talhouk RS et al (2008) Gap junctional intercellular communication in hypoxia-ischemia-induced neuronal injury. Prog Neurobiol 84(1):57–76
69. Frantseva MV, Kokarovtseva L, Perez Velazquez JL (2002) Ischemia-induced brain damage depends on specific gap-junctional coupling. J Cereb Blood Flow Metab 22(4):453–462
70. Chung H et al (2007) Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. Endocrinology 148(1):148–159
71. Andrews ZB (2011) The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci 34(1):31–40
72. Rothman SM (1983) Synaptic activity mediates death of hypoxic neurons. Science 220(4596):536–537